Skip to main content

Table 1 Demographic and clinical characteristics of the study population

From: Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial

  

Study group

Control group

p-value

Subjects

 

155

161

 

Age (years), mean (SD)

51.74 (12.05)

50.74 (13.12)

0.4801

Gender, n (%)

Female

99 (63.9)

102 (63.4)

0.9239

Male

56 (36.1)

59 (36.6)

Ethnicity (%)

Caucasian

145 (93.5)

147 (91.3)

0.6215

Latin American

7 (4.5)

10 (6.2)

Other

3 (2.0)

4 (2.5)

Time since diagnosis (months), mean (SD)

58.89 (93.29)

61.52 (95.80)

0.8050

Main diagnosis, n (%)

Major depression

146 (94.2)

148 (91.9)

0.7035

Dysthymic disorder

5 (3.2)

8 (5.0)

Other non-specified depressive disorder

4 (2.6)

5 (3.1)

Clinical Global Impression-Severity (CGI-S) scale, clinician-rated, mean (SD)

4.50 (0.62)

4.40 (0.57)

0.1663

Hamilton Depression Rating Scale (HDRS-17), mean (SD)

19.47 (5.96)

19.01 (5.71)

0.4818

Patient Global Impression of Improvement scale (PGI-I), single-blinded inclusion criterion, n (%)

No change

108 (69.7)

123 (76.4)

0.4026

A little worse

26 (16.8)

20 (12.4)

Much worse

16 (10.3)

16 (9.9)

Very much worse

5 (3.2)

2 (1.2)

Previous failed psychiatric medication trials, mean (SD)

 

2.55 (2.35)

2.57 (2.10)

0.9175